Association between β1 adrenergic receptor gene Arg389Gly polymorphism and risk of heart failure: a meta-analysis

St, Ma; Zhao, Wei; B, Liu; Ry, Jia; Cj, Zhao; Lq, Cui

doi:10.4238/2015.june.1.9

Cited by 5 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The beneficial effects of β-blockers in patients with heart failure and impaired ejection fraction was mainly because of a class effect, as no statistics from currently available trials evidenced the advantage of any single agent over other treatments. Ma et al conducted a meta-analysis on the correlation between β1-adrenergic receptor gene Arg389Gly polymorphism and risk of heart failure in humans ( 49 ). The studies were mined from the PubMed, Embase, and China National Knowledge Infrastructure databases and two reviewers independently evaluated the studies.…”

Section: Resultsmentioning

confidence: 99%

A meta-analysis of the effects of β-adrenergic blockers in chronic heart failure

Zhang

Shen

Zhai

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Adrenergic β-blockers are drugs that bind to, but do not activate β-adrenergic receptors. Instead they block the actions of β-adrenergic agonists and are used for the treatment of various diseases such as cardiac arrhythmias, angina pectoris, myocardial infarction, hypertension, headache, migraines, stress, anxiety, prostate cancer, and heart failure. Several meta-analysis studies have shown that β-blockers improve the heart function and reduce the risks of cardiovascular events, rate of mortality, and sudden death through chronic heart failure (CHF) of patients. The present study identified results from recent meta-analyses of β-adrenergic blockers and their usefulness in CHF. Databases including Medline/Embase/Cochrane Central Register of Controlled Trials (CENTRAL), and PubMed were searched for the periods May, 1985 to March, 2011 and June, 2013 to August, 2015, and a number of studies identified. Results of those studies showed that use of β-blockers was associated with decreased sudden cardiac death in patients with heart failure. However, contradictory results have also been reported. The present meta-analysis aimed to determine the efficacy of β-blockers on mortality and morbidity in patients with heart failure. The results showed that mortality was significantly reduced by β-blocker treatment prior to the surgery of heart failure patients. The results from the meta-analysis studies showed that β-blocker treatment in heart failure patients correlated with a significant decrease in long-term mortality, even in patients that meet one or more exclusion criteria of the MERIT-HF study. In summary, the findings of the current meta-analysis revealed beneficial effects different β-blockers have on patients with heart failure or related heart disease.

show abstract

Section: Resultsmentioning

confidence: 99%

A meta-analysis of the effects of β-adrenergic blockers in chronic heart failure

Zhang

Shen

Zhai

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…HF is one of the most common causes of hospitalization and death of patients. It is known that the course of HF, its progression, is associated with comorbidities and the dynamics of a number of biomarkers, hormones and genetic factors [7]. NTG is a diffuse or nodal enlargement of the thyroid gland, which is not due to an inflammatory or neoplastic process and is not associated with impaired gland function.…”

Section: Discussionmentioning

confidence: 99%

ASSOCIATION OF Β-Adrenoreception SYSTEM GENE POLYMORPHISMS AND NON-TOXIC GOITER IN PATIENTS WITH HEART FAILURE*

Pyvovar

Rudyk

Lozyk

et al. 2019

Med. and Ecol. probl.

View full text Add to dashboard Cite

Predicting the course of heart failure (HF) is an urgent task of modern medical science. Given the increasing prevalence of the disease with age, it is necessary to take into account the presence of comorbid pathology. The aim of the research was to study the relationship between gene polymorphisms of the β-adrenoceptor system with non-toxic goiter (NTG) and the HF course. Materials and methods. The total of 285 patients with HF against the background of post-infarction cardiosclerosis were included into the study. Of these, 158 (55.42%) patients had a comorbidly unfavorable pathology - NTG. Genotyping of 4 polymorphisms (Gly389Arg of the β1-adrenoreceptor gene, Ser49Gly gene of the β1-adrenoceptor (β1-AP) gene, Gln27Glu of the β2-AP gene and Ser275 of the β3- G-protein subunit gene was performed usingpolymerase chain reaction (PCR). Genetic and epidemiological analysis was performed using the SNPStats software. The obtained results. The presence of the G-allele of the Ser49Gly polymorphism of the β1-AP gene is associated with an increase in the rate of NTG development (recessive heredity model, x2 = 3.719, p = 0.039). We found a tendency to the increase of NTG development rate (by 5.9%) in the presence of the allele C polymorphism of Ser275 gene GNβ3 (recessive model of heredity, x2 = 3,452, p = 0,068). The risk of "low triiodothyronine" syndrome development in patients with HF, running against the background of NTG increases in homozygotes (G / G) according to the polymorphism Ser49Gly (c, 145A> G) of the β1-AR gene (odds ratio (OR) = 9.19 (3.69-22.90), g = 0.044). In patients with HF, which runs against the background of NTG, with the presence of the G allele polymorphism Gln27Glu (c, 79C> G) of the β2-AP gene, the risk of reaching a combined endpoint within two years (OR = 3.05 (1.10-8.43) increases in a homozygous state and OR= 3.38 (1.47-7.82) in heterozygotes, at p = 0.008), the risk also increases with heterozygous (G / C) patients with the Gly389Arg (c, 1165G> C) polymorphism of the β1-AR gene in the presence of NTG (OR = 2.09 (1.00-4.37), p = 0.046). Conclusion. Congenital genetic differences in -adrenoceptor pathways may be associated with the development of non-toxic goiter and the long-term course of heart failure.

show abstract

Cardiac autonomic innervation

Jamali

Waqar

Gerson

2017

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

The autonomic nervous system plays a key role in regulating changes in the cardiovascular system and its adaptation to various human body functions. The sympathetic arm of the autonomic nervous system is associated with the fight and flight response, while the parasympathetic division is responsible for the restorative effects on heart rate, blood pressure, and contractility. Disorders involving these two divisions can lead to, and are seen as, a manifestation of most common cardiovascular disorders. Over the last few decades, extensive research has been performed establishing imaging techniques to quantify the autonomic dysfunction associated with various cardiovascular disorders. Additionally, several techniques have been tested with variable success in modulating the cardiac autonomic nervous system as treatment for these disorders. In this review, we summarize basic anatomy, physiology, and pathophysiology of the cardiac autonomic nervous system including adrenergic receptors. We have also discussed several imaging modalities available to aid in diagnosis of cardiac autonomic dysfunction and autonomic modulation techniques, including pharmacologic and device-based therapies, that have been or are being tested currently.

show abstract

Association between β1 adrenergic receptor gene Arg389Gly polymorphism and risk of heart failure: a meta-analysis

Cited by 5 publications

References 17 publications

A meta-analysis of the effects of β-adrenergic blockers in chronic heart failure

A meta-analysis of the effects of β-adrenergic blockers in chronic heart failure

ASSOCIATION OF Β-Adrenoreception SYSTEM GENE POLYMORPHISMS AND NON-TOXIC GOITER IN PATIENTS WITH HEART FAILURE*

Cardiac autonomic innervation

Contact Info

Product

Resources

About